Trial Profile

Open-label Extension Study of Long-term Safety and Efficacy of NNC6019-0001 in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 09 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Coramitug (Primary) ; Buclizine; Cetirizine; Gadoterate-meglumine; Potassium chloride; Pseudoephedrine
Indications Cardiomyopathies
Focus Therapeutic Use
Sponsors Novo Nordisk; Prothena

Most Recent Events

18 Sep 2025 Status changed from recruiting to active, no longer recruiting.
04 Aug 2025 According to a Prothena media release, a clinical milestone could be achieved in 2026 if prespecified enrollment criteria are met in a Phase 2b or Phase 3 clinical trial being conducted by Novo Nordisk.
16 Sep 2024 Planned End Date changed from 28 Aug 2028 to 15 Aug 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com